Business Context and Reporting Period
This Form 8-K Current Report was filed by DiaMedica Therapeutics Inc. on March 6, 2023, covering events that occurred on March 1, 2023. The Company is a clinical-stage biotechnology firm incorporated in British Columbia with its principal executive offices in Minneapolis, Minnesota. The report focuses on changes to the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to executive compensation:
- Stock Option Grant: 26,443 options granted to the new director at an exercise price of $1.77 per share.
Material Changes
The filing reports the following material changes to corporate governance:
- Director Resignation: Amy L. Burroughs resigned as a director on March 1, 2023. The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Tanya N. Lewis was appointed to the Board of Directors effective March 1, 2023, to fill the vacancy.
- Compensation Arrangement: Ms. Lewis received an option grant vesting in 12 quarterly installments over three years, contingent on her continued service as a director. She will also receive customary non-employee director compensation.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks. It notes that Ms. Lewis brings significant regulatory and development experience from her roles at Replimune Group, Inc., Karyopharm Therapeutics Inc., and other biopharmaceutical companies. The Company entered into a standard indemnification agreement with Ms. Lewis.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 26,443 options granted to Tanya N. Lewis.
- Review the Company's most recent Proxy Statement for details on standard non-employee director compensation.
- Confirm the absence of any undisclosed disagreements regarding Amy L. Burroughs' departure.
- Check the attached Press Release (Exhibit 99.1) for additional context on the appointment.